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ABSTRACT 
 
An effective antibody response is essential for immunity against influenza (Flu) 
virus infection and is the primary goal for Flu vaccines.   In this study, codon optimized 
and wild type DNA vaccines expressing hemmaglutinin (HA) antigens of human flu 
viruses A/H1N1/NewCal/20/99 (H1 serotype) were compared.  Expression levels of HA 
antigens were increased in 293T cells transiently transfected with codon optimized as 
compare to the wild type HA gene construct.  The codon optimized vaccine was able to 
elicit a greater immune response in rabbits and mice as measured by ELISA testing of the 
temporal response and end antibody titers.   
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BACKGROUND 
 
Influenza related sicknesses have become a global commonality during the winter 
months.  The influenza virus belongs to the Orthomyxoviridae, enveloped viruses with a 
segmented single-stranded RNA genome (Palese and Garcia-Sastre, 2002).  It is a highly 
contagious virus that attacks the upper respiratory tract and has plagued the world since 
nearly the beginning of written history.  The “flu,” as it is commonly known, primarily 
causes achy muscles, fever and digestive system symptoms in humans, although it can 
cause death in people with complications in hosts with weakened immune systems 
(Langley and Faughnan, 2004).  Some strains, however, cause global pandemics of 
catastrophic proportions such as the Spanish influenza of 1918-1919 during which up to 
50 million of people were killed worldwide, regardless of the status of their immune 
system (Palese and Garcia-Sastre, 2002).  According to the World Health Organization 
(WHO), we are due for another pandemic with a human adapted form of the avian flu as 
the leading potential strain.  Global pandemics of the past reached all continents in 6-9 
months, but with easier travel, the next pandemic could infect all continents in less than 3 
months (WHO, 2005). 
 
Virological Features of Influenza Virus 
Types of Influenza Virus 
 There are three types of influenza currently in existence, types A, B and C.  Types 
A and B are morphologically indistinguishable, while type C is differentiated by its 
glycoprotein spikes.  The morphological differences will be discussed later.  Infectiously, 
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type A can spread among both humans and animals, while type B affects only humans, 
and type C affects predominantly humans, but recently also infected swine in China.  The 
type A virion is also described by the subtypes of hemagglutinin (HA protein) 15 
subtypes, and neuraminidase (NA protein) 9 subtypes, protein spikes on the virus surface 
(Lamb and Krug, 1996; Murphy and Webster, 1996).  For example, the current avian flu 
strain (H5N1), which currently is not readily transmittable to humans, is an influenza A 
virus with a type 5 HA protein with a type 1 NA protein.  New influenza virus strains 
result primarily from antigenic changes of the hemagglutinin and neuraminidase proteins.   
Antigenic drift results from point mutations that occur during viral replication within a 
major serotype, and antigenic shift occurs when genes from animal influenza viruses are 
captured by the human virus via reassortment usually resulting in high mortality (Palese 
and Garcia-Sastrem, 2002).   
 
Morphology of Influenza Viruses 
The influenza virus is comprised of RNA, proteins, lipids and carbohydrates.  The 
most striking features of the influenza virion are the mushroom shaped neuraminidase 
proteins and rod shaped hemagglutinin proteins (Figure 1).  The NA and HA protein 
extend through the lipid bilayer and into the M1 matrix protein.  Types A, B and C also 
encode transmembrane proteins M2, NB and CM2 respectively.  The proteins are used as 
ion channels.  The outermost layer of the virus is a lipid bilayer, and under that is M1 
matrix protein.  The matrix protein is thought to interact with the ribonucleoproteins 
(RNPs) in the nucleus of the virus (Lamb and Krug, 1996).   
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 Figure 1: Morphology of the influenza virus.  Note the Neuraminidase (black) and rod-like 
Hemagglutinin proteins (gray), the primary antigenic components of the virus.  
 
The number of RNA segments in the types of virions differ; type A and B have 
eight strands, while type C has only seven strands.  Type C lacks an RNA segment for 
NA, although the glycoprotein HEF mimics some of the missing NA functions which 
take place in type A and B viruses.  Each of the eight strands has an associated 
transcriptase complex containing proteins PB1, PB2 and PA.  Strand number one is 
longest, while strand number eight is shortest in length.  The RNP is formed from the 
interaction of the nucleocapsid protein and an RNA strand (Lamb and Krug, 1996).   
 
Protective Antigens 
The hemagglutinin protein appears to be the most important surface protein.  Its 
rod shape makes it ideal for penetration of the virus into the cytoplasm of the cell it is 
trying to infect.  The penetration allows for the eventual release of the viral nucleocapsids 
into the cell (Lamb and Krug, 1996).  Hemagglutinin is also the primary protein to which 
antibody responses are mounted against.  The HA protein is expressed in the whole unit 
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form HA0 that is proteolytically cleaved into two subunits, HA1 and HA2, which are 
held together by a single disulfide bond.  The HA1 subunit forms the orbicular head of 
the molecule, comprised of the receptor binding site and conformationally dependent 
epitopes to which neutralizing antibodies are primarily mounted against (Dowdle et al., 
1974; Koopmans et al., 2004; Webster et al., 1975).  The HA2 subunit anchors the 
molecule into the lipid membrane and is highly conserved among various influenza virus 
strains.  Cleavage into HA1 and HA2 is required for the virus to become infectious 
making it a critical determinant in the ability of the virus to spread (Lamb and Krug, 
1996). 
Neuraminidase is mushroom shaped, dispersed throughout the membrane (Hay, 
1974) and permits the transport of the virus through the mucus membrane of the 
respiratory tract allowing the virus to find its target epithelial cells.  It is known that the 
NA polypeptide is not present in influenza type C viruses.  This suggests that HA is 
involved in the budding process in viral replication.  Some less common avian 
neuraminidases have a receptor binding site that causes hemagglutination (Murphy and 
Webster, 1996).   
 
Replication 
 Entry of the virion into the target host cell is facilitated by the binding of the 
hemagglutinin spikes to the sialic acid of the target cell (Skehel and Wiley, 2000).  This 
binding can be reversed by polysaccharide cleavage by neuraminidase spikes.  It is 
advantageous for the virus to do this because it prevents virus from being concealed by 
inappropriate cell types or in mucus.  Sialic acid is common on cell surfaces in mucus 
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and would neutralize the virus, rendering it useless.  After binding, the cell engulfs the 
virus by endocytosis via endosomes.  The vesicle is then acidified by the cell which 
allows for trypsin-like enzymes to cleave the HA (hemagglutinin) monomers.  This 
process activates the membrane-fusion function and since the virus envelope and the 
endosome’s membrane are so close to each other, they fuse together to form one 
membrane (Lamb and Krug, 1996).  
 
Figure 2: Influenza Virus Replication.  The virus attaches itself to the outside of a host cell (upper part of 
diagram) and it enters the cell as a vesicle.  The viral genes are transcribed and translated by the cell's 
enzymes and ribosomes.  Now instead of producing only new cellular material, the cell produces many new 
virus particles. The new virus particles are eventually released via budding (diagram right side), and infect 
their own host cells. (Lamb and Krug, 1996) 
 
Next, a target sequence begins in the nucleocapsid protein that results in passage 
of the nucleocapsid into the nucleus.  When the virus first infects the cell, replication 
cannot occur because host cell DNA synthesis is required and virus replication is blocked 
by antibiotics like mitomycin C.  Later, a protein is cleaved off of the RNA strand and a 
cap is exposed that acts as a primer.  PB1 and PA complete the synthesis of the (+) sense 
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strand.  There are two types of (+) sense RNA formed, incomplete which serve as mRNA, 
and cRNA which serve as templates for the synthesis of daughter (-) sense vRNAs.  Most 
of the proteins created stay in the cytoplasm, but the NP protein drifts back to the nucleus 
where it interacts with the new vRNAs to form new nucleocapsids.  Finally, the HA and 
NA proteins in the cytoplasm attach to a newly formed cell membrane which is exported 
from the host cell via budding (Murphy and Bang, 1952; Murphy and Webster, 1996).   
 
Transmission and Prevention 
 Influenza virus is easily spread through the air when an infected person coughs or 
sneezes.  The virus enters the body through the mouth or nose.  It generally takes one to 
four days for a person to exhibit symptoms, and the person is infectious for up to seven 
days following the first signs of symptoms.  The virus survives most easily in cold and 
dry weather, making the population most susceptible during the winter months (Center 
for Disease Control, 2005).   
 Prevention techniques include frequent hand washing, avoid touching eyes, nose 
and mouth, and coughing and sneezing into a tissue that is promptly thrown away.  There 
are currently three antiviral drugs on the market (amantadine, rimantadine, and 
oseltamivir) approved for flu treatment and prevention.  The foremost prevention 
measure is vaccination.  There are currently two different methods of administering flu 
vaccines.  The most common is made of an inactive type that is administered via 
intramuscular injection.  The newest vaccine is administered through a nasal spray and is 
composed of live attenuated influenza virus (LAIV).  Each year, a new vaccine is 
produced that contains three virus strains, two A strains and one B strain, strains 
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presumed to reach the United States during the next winter flu season.  The attenuated 
version of the vaccine is still capable of replication so it is only recommended for healthy 
people ages five to forty-nine, while the inactivated virus vaccine can be given to anyone 
over the age of six months (CDC, 2005).   
 
 
Current Influenza Vaccines 
 There are currently two different influenza vaccines used, inactivated and live 
attenuated viruses.  The flu vaccines used in the United States are trivalent, consisting of 
three different strains forecasted to arrive in the U.S. by the World Health Organization.  
The strains present in the United States as of December 3, 2005 were two type A viruses 
H3N2 and H1N1, as well as a type B virus (CDC, 2005).  The inactivated vaccines are 
grown in eggs, then purified and inactivated with chemicals to make it non-infectious.  
The effectiveness of the vaccine depends on the levels of similarity between the virus 
strains present in the population and the strains present in the vaccine, as well as the 
strength of a person’s immune system and their age (Palese and Garcia-Sastre, 2002).  
The live attenuated vaccines are created from the same three strains predicted by the 
WHO.  The vaccine is based upon a master strain which is grown in eggs at low 
temperature and over many growth cycles as a way to increase the antigen variability.  
The vaccine is administered via a nasal spray instead of a needle injection, but is only 
recommended for healthy people between the ages of 5-49 years old.  The age restrictions 
are in place because the virus is only weakened, people with compromised immune 
systems because of age and/or disease can be susceptible to influenza viral replication 
and sickness (CDC, 2005).  There are more vaccines in development such as a universal 
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flu vaccine based upon the antigenicity of the M2 protein (Fan et al., 2004; Neirynck et 
al., 1999) and reverse genetics of the flu DNA plasmid (Palese and Garcia-Sastre, 2002).   
 
DNA Vaccines 
 DNA vaccines are based upon the premise that only a portion of a virus’ antigens 
delivered in the form of DNA is needed to mount a sufficient immune response to combat 
infection.  Naked DNA is transfected into target cells and the cells produce the proteins.  
DNA vaccines are an effective way to create immunity because the antigens are produced 
within host cells and therefore are presented via both MHC-I and MHC-II pathways.   
DNA vaccines elicit a response in both the humoral (antibodies) and cellular (cell 
mediated) arms of the immune system (Lu et al., 1996; Lu et al., 1998; Robinson et al., 
1999).  Inactivated vaccines are not effective in generating strong immune responses, 
especially poor cell mediated immune responses (Johnson et al., 1999).  Live attenuated 
vaccines are more effective but there is always safety concerns and people with 
compromised immune system can not use live attenuated vaccines. 
 The amount of DNA required to mount a sufficient immune response varies 
between inoculation methods although amounts are usually measured in micrograms.  
There are three most common methods of inoculation: particle bombardment (gene gun), 
intramuscular injection (i.m.) and intradermal injection (i.d.).  In the current study, both 
the gene gun and intramuscular injections were used in the mouse study and only the 
gene gun was used in the rabbit study.  There are advantages and disadvantages to both 
inoculation methods.  Less DNA is required for gene gun inoculation than i.m. or i.d. 
injections, but i.m and i.d. may require more immunizations (Bohm et al., 1996; Hartikka 
et al., 1996).  Intramuscular or intradermal injections are a variable technique because 
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experience and ability differs between researchers, whereas the gene gun method 
provides a more consistent result.  The transfection efficiency of target cells is higher 
when using the gene gun, since the DNA is bombarded into the cells. The DNA dose 
required to elicit a good immune response in mice via i.m. injection ranges from 50 to 
100 µg, while gene gun inoculation required only 6 µg at each immunization. 
DNA is easy to engineer allowing for specific sequences to be designed as a way 
to increase immunogen variability.  Different leader sequences, promoters and other 
subunits can be utilized to maximize the translational process as well as codon 
optimization which is discussed later.  An example is the addition of a human tissue 
plasminogen activator (tPA) leader sequence which can accelerate the humoral antibody 
responses in rabbits against spike protein which is the protective antigen against the 
SARS associated coronavirus (Wang et al., 2005).  Since only portions of viral DNA are 
used, there is no chance for subsequent infection after vaccination as there is when using 
live attenuated vaccines.  Vaccines based on retroviral vectors always run the risk of 
becoming pathogenic or integrating into the host cell’s genome with the possibility of 
carcinogenesis.  However, adenoviral vectors are not pathogenic and are not integrative, 
but they do cause a strong immune response against the vector, hindering its effectiveness.  
 
Influenza DNA Vaccines 
 Past DNA vaccines against the flu have yielded both positive and negative results.  
In a phase I clinical trial, Merck tested a DNA flu vaccine and assayed for cell mediated 
immunity.  It had been hoped that cell mediated immunity (CMI) was the way to combat 
influenza (Donnelly et al., 1995), but the Merck trial failed to yield a detectable target 
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result for possibly two reasons: their assays were not effective enough at measuring CMI 
levels, or their DNA vaccine was not optimized enough via a method like codon 
optimization for example.  On the other hand, it was demonstrated that there was 
complete protection from a lethal dose of influenza virus from as little as 1 µg DNA 
given in two doses (Deck et al., 1997).   The DNA vaccines for influenza currently being 
developed in the laboratory of Shan Lu, University of Massachusetts Medical School, 
have shown in mouse and rabbit animal studies that a significant antibody response can 
be mounted (data in results).   
 An influenza DNA vaccine can be paired with other combinations of flu vaccines 
to create an increased immune response.  It has been shown that a prime-boost method of 
immunization elicits a greater immune response as opposed to using one or the other 
modality alone (Richmond et al., 1998).  Following this method, the DNA flu vaccine 
could be used as an immune primer, and an inactivated flu vaccine could be used to boost 
immunity.  The inactivated flu vaccine does not create a lasting immune response unless 
there is a primer present. If the flu DNA vaccine is administered first then boosted with 
the inactivated vaccine, a smaller dose of the inactivated vaccine will be needed which 
hopefully could help prevent dose shortages as seen in the flu season of 2004.   
 
Codon Optimization 
 Codon Optimization is performed as a way to increase protein expression in 
organisms by making the translation of a gene of interest more efficient from one 
organism to another, e.g. viral DNA sequence to be expressed in human cells.  The amino 
acid sequence of the viral protein remains the same, while the triplet of base pairs (codon) 
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is altered to match the codon preferences in the new organism that are most frequent.  
Codons of low frequency in the original DNA are altered to codons of high frequency in 
the organism the DNA is being introduced to.  It has been determined that there is a direct 
correlation between translational efficiency, which leads to high expression levels, and 
immunogenicity in host species.  Nagata et al. (1999) showed that the amount of codon 
optimization of a gene directly correlated with the translational efficiency in mammalian 
cells.    
 The influenza A genome is codon biased meaning that some codons are more 
common than others, or that natural selection can distinguish between synonymous 
codons, or both even (Plotkin and Doshoff, 2003).  The most commonly accepted 
explanation of codon bias states that codon appearance is optimized to match the amount 
of isoaccepting tRNAs available, allowing for an increased translational efficiency 
(Zuckerkandl and Pauling, 1965; Ikemura, 1981).  Other theories include that codon bias 
is a result of selection for regulatory function mediated by ribosome pausing (Lawrence 
and Hartl, 1991) or selection against codons that lead to early termination (Fitch, 1980; 
Modiano et al., 1981).  Whichever the explanation may be, the determination of which 
codons occur most frequently can be used to increase the efficiently of mRNA translation.  
The codon usage is different from mutations at the epitopic regions of the HA1 antigen 
which has more frequent mutations than others (Plotkin and Doshoff, 2003).   
 André et al. (1998) created a HIV gp120 codon optimized DNA vaccine, 
syngp120, and performed cellular transfections and BALB/c mice studies.  All wild type 
codons were replaced by codons found in human genes that are most highly expressed.  
The group found that codon optimized expression levels were significantly higher than 
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WT levels among various assays.  In 293T cells, expression levels increased 10-50 fold in 
the optimized sequence, in BALB/c mice, the synthetic sequence produced greatly higher 
antibody titers from ELISA showing an increased humoral response.   
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Project Purpose 
  
The purpose of this project was to use ELISAs and western blots to determine the 
immunogenic and expression differences respectively of wild type and codon optimized 
H1 influenza DNA vaccines.  Mice, rabbits and 293T cells were used as model systems 
to fully understand and enumerate the ability to improve the immunogenicity under a 
variety of conditions.  This research will provide useful information and lay groundwork 
for future experiments involving other influenza DNA vaccines as well as studies on B 
cell memory. 
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Materials and Methods 
 
DNA Sequences 
 The influenza H1 strain A/H1N1/NewCal/20/99, GenBank accession number AJ 
344014, was used as a wild type baseline for experiments.  Codon optimized constructs 
were created by Geneart (Regensburg, Germany) from the wt sequence into a G + C rich 
content found in humans.  The gene inserts were ligated into vector pSW3891. 
 
Recombinant DNA Techniques 
Agarose Gel Electrophoresis 
 
Agarose was dissolved in TAE buffer to a 1% (w/v) concentration.  The mixture 
was then heated in a microwave oven until the agarose was completely dissolved.  A Bio- 
Rad agarose gel casting system was used to pour the gel and after the agarose cooled 
down, samples were loaded with 6X loading buffer.  The gel was run in a Bio-Rad gel 
box at approximately 50-70 Volts for one and a half to two hours.  After that, the gel was 
stained in an Ethidium Bromide solution (25 ng/ml in TAE buffer) for 20-30 min.  The 
stained gel was then  photographed using an Olympus COMEDIA Master System 4.1TM 
digital camera under UV light. 
 
Restriction Endonuclease Digestion 
 
The final volume for restriction enzyme digestions was 15 µl for single digestions, 
and 20 µl for double digestions.  The appropriate enzyme concentration and buffer, BSA, 
sterile H20, and DNA concentrations were estimated according to the New England 
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BioLabs catalogue.  DNA was digested at 37˚C for one and a half hours then analyzed on 
an agarose gel. 
 
In vitro Expression of Influenza H1.HA0 Antigens 
 
The expressions of H1 DNA vaccine constructs were examined by transient 
transfection of 293T cells (Pear, 1993).  Transfection was performed when cells were at 
approximately 50% confluence on 100mm dishes by calcium phosphate coprecipitation, 
using 20 µg of plasmid DNA per dish.  The supernatants and cell-lysates were harvested 
72 h after transfection.  The H1 protein expression was confirmed by Western blot.  A 
quantitative enzyme-linked immunosorbent assay (ELISA) was used to measure the 
amounts of H1 produced from each DNA construct.  A known amount of recombinant 
H1 protein was used to establish the standard curve. 
 
DNA Vaccination Techniques 
DNA Tubing Preparation 
 
For all the procedures in this section, a Bio-Rad tubing prep station was used. 
Rislan tubing was dried for 1–2 hours by forcing N2 at ~ 0.2 L/min into the tubing.  The 
ends of the tubing were capped after drying to keep moisture out.  Water was added to 1 
µm gold beads (adjusted for each experiment) to achieve a final concentration of 100 
mg/ml.  The gold beads were centrifuged to the bottom of a microcentrifuge tube for ~10 
seconds and the water was removed with a pipette, leaving a small amount of water (~50 
µl) in the tube.  A 100 µl aliquot of spermidine (100 mg/ml in water) was added to the 
gold bead pellet, and the mixture was vortexed thoroughly at high speed until the gold 
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was completely re-suspended. Plasmid DNA was added to the beads/spermidine 
suspension.  The mixture was vortexed only briefly on high, as the DNA can shear easily. 
CaCl2 (2.5 M in water) was added drop-by-drop into the mixture while vortexing at 
medium speed.  The mixture was let stand at room temperature for 3-5 minutes to allow 
precipitation, and then centrifuged for 8 seconds, decanted and the supernatant was 
discarded.  The coated gold beads were washed 5 times with 1ml dehydrated absolute 
ethanol.  Each time, the ethanol-resuspended beads were centrifuged for 8-12 seconds 
and the supernatant removed.  The beads were resuspended in the total volume of 
absolute ethanol needed for each preparation in a 20 ml glass scintillation vial and capped 
tightly.  A piece of tubing 2 –3 inches beyond the right end of the tubing prep station was 
cut. A 10 ml syringe was attached to the right end of the cut tubing.  The glass vial of 
gold beads was sonicated briefly to completely suspend the beads, and the suspension 
was drawn into the tubing with a syringe.  The gold was allowed to settle out of the 
suspension in the tubing for 10 minutes.  Then the ethanol was slowly drawn from the 
tubing with the syringe at a rate of about 2 inches per second.  The tubing was connected 
to the nitrogen port and the prep station was turned on to rotate the tubing and spread the 
gold over the inside of the tubing for 1 minute.  The nitrogen flow was turned on to 0.4 
L/min to dry the remaining ethanol from the tubing for 5 minutes as it continued to rotate. 
The tubing was cut into half- inch cartridges using the tubing cutter, sealed in a 
scintillation vial with parafilm, and stored at –20˚C. 
 
Anesthesia, Immunization and Bleeding 
 
Rabbits 
A portion of skin was cleaned for the injection of anesthetic solution into the right 
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hind leg quadriceps or lumbar muscle of each animal.  The anesthetic solution consisted 
of Ketamine (100 mg/ml)/Xylazine (100 mg/ml)/saline.  The total volume of the 
anesthetic solution each animal received was calculated based on the animal’s weight 
(see table V).  Rabbits were then bled from the central ear vein.  The backside of the ear 
was rubbed briskly with an alcohol prep.  Then, using a 23-gauge butterfly needle, blood 
was removed with a syringe until the desired amount was collected.  The blood was then 
transferred to a vacuum tube.  The animal’s abdomen was then shaved, and DNA-coated 
gold beads were inoculated to the shaved surface using the gene gun.  Each animal 
received 36 µg of DNA per dose, and four doses were administered according to the 
schedule in table I . 
 
 
Table I: Dose and composition of the anesthetic solution injected to the rabbits 
 
 
Mice 
The abdominal fascia was rubbed with an alcohol prep, and 0.5-0.7 µl of 
anesthetic solution (Ketamine (100 mg/ml)/Xylazine (100 mg/ml)/Saline 4:1:10) was 
injected intraperitoneally using a tuberculin syringe.  Once the animals were sedated, a 
glass capillary tube was used to draw blood from the periorbital cavity.  The abdominal 
area was then shaved, and DNA-coated gold beads were inoculated using the gene gun.  
Each animal received 3 doses of 6 shots each according to the schedule in table IV. 
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DNA Immunization 
Mice 
Female Balb/C mice, 6–8 weeks old, were purchased from Taconic Farms 
(Germantown, NY) and housed in the animal facility managed by the Department of 
Animal Medicine at the University of Massachusetts Medical School in accordance with 
IACUC approved protocol.  The animals received three monthly DNA immunizations by 
a Bio-Rad Helios gene gun (Bio-Rad, Hercules, CA).  The original sequence or codon 
optimized H1-expressing DNA pSW-3891 plasmids were coated onto the 1.0 µm gold 
beads at 2 µg of DNA/mg of gold.  Each shot delivered 1 µg of DNA and a total of six 
non-overlapping shots were delivered to each mouse at the shaved abdominal skin after 
animals were anesthetized.  The serum samples were collected immediately before, and 2 
weeks after each immunization. 
 
 Groups         #  of Mice           DNA Vaccine 
    A                     10                   Saline I.M. (control) 
    B                     10                   wt I.M.   
    C                     10                   opt I.M. 
    D                     10                   wt G.G. 
    E                     10                    opt G.G. 
Table II: Animal Groups and Immunizations Administered for the Mouse 
Experiment. The table shows the composition of the DNA vaccine used to 
inoculate the mice in each group.  Each mouse was given 100 µg of DNA per immunization 
for I.M. injection while the gene gun mice received 6 µg of DNA per immunization. 
 
Immunization I II III IV   V  
Bleed I II III IV V VI VII VIII 
Week # 1 3 5 9 11 12 14 16 
Table III: Immunization and Bleeding Schedule for the Mouse Experiment 
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Rabbits 
Female New Zealand White rabbits weighing 2 kg were purchased from 
Millbrook Breeding Lab (Amherst, MA).  Animals were housed in the facility managed 
by the Department of Animal Medicine at the University of Massachusetts Medical 
School following IACUC-approved protocols.  Rabbits received four DNA 
immunizations by a Helios gene gun (Bio-Rad, Hercules, CA).  A H1 original sequence 
or codon optimized DNA vaccine plasmid was coated onto the 1.0-µm gold beads at 2 µg 
of DNA/mg of gold so that each shot delivered 1 µg of DNA.  At each immunization, the 
rabbits were anesthetized, and a total of 36 nonoverlapping shots were delivered to the 
shaved abdomen.   
 
Group               Rabbit #                          DNA Vaccine 
    1                     316-317                        codon optimized 
    2                     381-382                  wt A/H1N1/NewCal/20/99 
Table IV: Animal Groups and Immunizations Administered for the Rabbit 
Experiment. The table shows the composition of the DNA vaccine used to 
inoculate the rabbits in each group. 
 
 
Immunization I II III  IV   
Bleed I II III IV V VI VII
Week # 1 3 5 7 9 11 13
Table V: Immunization and Bleeding Schedule for the Rabbit Experiments 
Immunological Techniques 
 
ELISA 
 
Concanavalin A (ConA) Antigen Capture ELISA for Detection of Antibody 
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96-well flat bottom plates were coated with 100 µl/well of Concanavalin A 
(ConA) at a concentration of 50 µg/ml in PBS, pH 7.4, and incubated for 1 hour at room 
temperature (RT).  The plates were washed with wash buffer 5 times: 3 times for 1 min, 
once for 15 min, and once fast.  100 µl/well of PBS diluted H1.HA0.dTM antigen at a 
1:10 or 1:5 dilution were added and allowed to incubate for 1 hour at room temperature.  
After that the plates were washed as above.  Free ConA binding sites were blocked with 
200 µl/well of blocking buffer (5% non-fat dry milk in whey dilution buffer) and 
incubated overnight at 4˚ C.  The plates were washed as above.  100 µl of anti- H1 rabbit 
sera at 1:5000 dilution or mouse sera at 1:1000 dilution in whey dilution buffer were 
added to the wells, serial dilutions were performed, and the plates were allowed to 
incubate for 1 hour at RT.  The plates were washed as before.  100 µl of biotinylated anti-
rabbit IgG at 1:5000 or anti-mouse at 1:1000 in whey dilution buffer were added to each 
well and allowed to incubate for 1 hour at RT.  The plates were washed again.  100 µl of 
streptavidin-conjugated horseradish peroxidase (HRPstreptavidin) at 1:10000 in whey 
dilution buffer were added to each well and allowed to incubate for 1 hour at RT.  The 
plates were washed as above. Fresh TMB (1 TMB tablet/0.05 M phosphate/citrate 
buffer/0.006% H2O2) substrate was prepared and 100 µl were added to each well 
allowing 3.5 min incubation time at RT.  The reaction was stopped by adding 25 µl of 
2M H2SO4 to each well, and the OD was read at 450 nm using a Dynex Opsys MRTM 
plate reader. 
 
SDS PAGE and Western Blots 
 
A 10 % Acrylamide/bis-acrylamide minigel was run with the supernatant and or 
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lysate obtained from harvesting the transfected 293T cells, for approximately 1.5 hours at 
50 mA.  Before loading into the minigel, samples were mixed with loading buffer and 
boiled for 3-5 minutes.  Using a semi-dry blotting apparatus, the protein was transferred 
to a PVDF membrane for 1.5 to 2 hours at aproximately 80 mA per gel.  The cut piece(s) 
of membrane was pre-treated by submerging it into methanol for 2 min, then it was 
transferred to ddH2O and washed, and finally it was soaked in transfer buffer.  A cut 
piece of 3MM WhatmanTM paper (soaked in transfer buffer) was placed on the anode of 
the blotting apparatus then the membrane, then the gel, then another piece of WhatmanTM 
paper.  After the transfer was done, the membrane was incubated overnight in 10 ml of 
blocking solution (PBS, Tween-20 0.1-0.2% v/v, I-BlockTM 0.1% w/v) at 4° C. 
Antibody stocks were diluted to the desired concentration (1:200 for rabbit sera) 
in blocking solution.  5 ml of the diluted antibody were added to each membrane and they 
were allowed to incubate for 1 hour on the rotator at low speed.  The membrane was then 
washed four times, 20 min each, with 20 ml of blocking solution, on the rotator at 
vigorous speed.  The membrane was then incubated with the secondary antibody solution 
(diluted 1:5000 in blocking solution) for 1 hour, on the rotator at low speed.  The 
membrane was then washed four times, for a total of 1.5 hours, with 20 ml of blocking 
solution, on the rotator at vigorous speed. 
Chemiluminescence was performed using the Tropix Western LightTM protein 
detection kit.  Two pieces of thin, transparent plastic, big enough to cover the membrane 
were cut. 1.5 ml of substrate was added per membrane.  The “sandwich” was allowed to 
incubate for 5 min.  The membrane was dried on a paper towel, and transferred to a new 
dry sandwich.  This was exposed in the darkroom for variable times. 
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RESULTS 
 
Codon Usage 
 Two different hemagglutinin based DNA vaccines were created to test variability 
in-vitro in 293T cells, and in-vivo in rabbit and mouse animal models.  Both a wild type 
and codon optimized sequence were used (Figure 3A).  Gene inserts were ligated into 
vector pSW3891 at BamH1 and Pst1 restriction enzyme sites (Figure 3B).  The wild type 
sequence was codon optimized to increase the level of preferred codon usage in 
mammalian cells.  The G + C content of the wild type gene was 41.24% while the codon 
optimized sequence was 60.13%, a dramatic improvement.  A codon preference value of 
1 indicates the same frequency of human preferred codons was used in this particular 
gene as would be expected from a human gene sequence.  A value below 1 indicates a 
lower frequency usage of human preferred, G + C rich, codons.  When a value greater 
than 1 is observed, it indicates a higher frequency of human preferred codons usage 
(Figure 4).   
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 Figure 3: DNA Construct Inserts and Vector.  Panel A: The wild type insert came from the influenza H1 
strain A/H1N1/NewCal/20/99.  The codon optimized insert was created with a greater G + C rich content to 
match human codon preferences.  The blue box from 1-23bp is the HA natural leader sequence while the 
black box at 528bp location is the HA transmembrane domain.  Panel B:  Visualization of the pSW3891 
vector to which the constructs were inserted between the Pst1 and BamH1 restriction enzyme cut sites. 
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Figure 4:  Influenza A H1 hemagglutinin (HA) gene codon preference.  Sequences 
analyzed are optimized in Panel A versus the original sequence in Panel B and were those 
used in the study.  Levels above 1.00 indicate strong codon preference for human 
environments and below 1.00 indicates the codons present are not preferred. 
 
Protein Expression 
In order to test expression levels of the optimized and wild type constructs, 
transient transfections and subsequent western blots were performed.  293T cells, a 
human embryonic kidney cell line, were inoculated with one of the two DNAs, and cell 
lysates and supernatants were collected.  The cell lysates were used for western blot 
analysis.  Antibody detection was performed using rabbit sera inoculated with H1-
HA0.tPA.dTM. As seen in Figure 5, the codon optimized DNA sequence was expressed 
at a significantly higher level than the wild type sequence.  At higher concentrations, the 
different is not as noticeable so lower concentrations must be used to visualize the 
expression level difference. 
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Figure 5:  Western blot of wild type (WT) and codon optimized (OPT) H1 
HA gene expressed in transfected 293T cells.  A 0.1 µg/µl transient 
transfection was used and a series dilution in loading buffer was performed on 
the H1 protein.  A portion of the blot is shown as a representation of results.  
The pSW3891 vector was used as a negative control.  
 
Immunogenicity  
Animal Studies 
 Two animal models were chosen to test immune response.  The mouse model 
used is more standardized and “genetically purer” than rabbits.  Rabbits on the other hand 
allow for more sera to be harvested and their immune response more closely parallels a 
human response.  The two specific animal models, Balb/c mice and White New Zealand 
rabbits were used because they are commonly used in vaccine studies and are highly 
documented in the literature.  It is important to use multiple model systems in order to 
best qualify and quantify results. 
Mice 
Five groups of Balb/c mice were immunized as described in the methods.  Two 
H1 DNA vaccines were tested, one codon optimized to a more G + C rich content and the 
other a non-optimized, wild type A/H1N1/NewCal/20/99.  As a measure of H1 specific 
antibody response in mice after inoculation with the DNA vaccine, ELISAs were 
performed as a way to quantify the levels of antibodies.  Each ELISA performed was 
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coated with the same H1.HA0.dTM antigen, although the antigen batch was changed on 
one occasion due to stock depletion.   
In both the gene gun and intramuscular injection methods, the codon optimized 
sequences elicited higher antibody responses (Figure 6).  The sera used were pooled from 
the 10 mice in each group.  Overall, the gene gun method produced higher antibody 
levels.  The gene gun (G.G.) immunized mice reached the linear phase sooner than the 
intramuscular (I.M.) mice because of the shortened lag phase associated with gene gun 
particle bombardment.  It can also be seen that both codon optimized sequences fall off 
towards the final bleeding of this ELISA while the wild type sequences continue to grow 
(Figure 6).   
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Figure 6: Temporal ELISA of mouse immune response to H1 DNA vaccine.  
H1.HA0.dTM antigen was produced from DNA in 293 T cells, and used to coat ELISA 
wells to capture H1-specific IgG.  Optimal results were seen from mice immunized with 
the codon optimized construct via gene gun.  Samples used were pooled from the 10 mice 
in each group.  Arrows indicate week at which an immunization was given. 
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A titration was performed to determine titer points as a way to quantify antibody 
levels (Figure 7).  It is a method to assess whether an immune response to a specific 
antigen has occurred in immunized animals. As the serum is diluted, the optical density 
(OD) reading should continually decrease.  Two primary results were expected and were 
found: 1. that the G.G. groups would have a higher titer than the I.M. groups, and 2. that 
the optimized groups would have a higher titer than the wild type groups.  Both of these 
results were found and were quite distinguishable (Figure 7).  A titer point is defined as 
the level at which during a titration, the OD value is twice the prebleed reading.  A three 
fold series dilution was performed starting at an initial dilution of 1:300 in whey dilution 
buffer.  The I.M. groups had a nine fold titer difference between the wild type and 
optimized groups while the G.G. groups had only a three fold difference (Figure 8).   
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Figure 7:  ELISA titration of mouse study pooled  sera.  Sera samples were from 
bleed V with a starting dilution of 1:300 then a 3x series dilution was performed.  Gene 
gun (G.G.) immunization elicited a great immune response as compared to intramuscular 
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(I.M.) inoculation.  The G.G. codon optimized sequence proved to be most immunogenic.  
Saline Bleed I was used as a pre-immunization control and background measure. 
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Figure 8:  IgG titer points of mouse study pooled sera.  Data based upon Figure 7.  
Highest points belonged to the codon optimized sequences and gene gun immunization.   
 
 
  
 When using pooled sera for ELISAs or other immunological assays, variability 
among individuals in a group is masked into an average.  In order to show the true 
variation in titers among the ten mice in each group, a titration ELISA was performed and 
titer points are shown below (Figure 9).  In each group, most mice had the same titers 
showing consistency in immunization technique, vaccine immunogenicity and animal 
health.  Group B and C, immunized via the intramuscular injection method, showed 
lower titers as compared to groups D and E which were immunized with a gene gun.  
Also, the wild type groups, B and D showed lower titers than the codon optimized mice 
in groups C and E.  Group E contains only nine animals (instead of ten) because one was 
prematurely terminated. 
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Figure 9: IgG titer points of mouse study individual mice.  Variability among animals in each 
group was small.  The highest points belonged to the codon optimized sequences (groups C and E) 
and gene gun immunization (groups D and E).   
 
Rabbits 
 
 This experiment was designed as a way to compare codon optimized and wild 
type H1 gene sequences in rabbits.  The two codon optimized construct rabbits, R # 316 
and 317, and two wild type construct rabbits, # 381 and 382, were immunized via gene 
gun.  Each rabbit was injected with 36 µg of DNA.  Immunizations were performed on 
weeks 1,3,5,9,14, and bleedings were performed on weeks 1,3,5,9,11,12,14,16.   A time 
course plot was created from ELISA data using all the seven bleeds collected (Figure 10).  
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The drop in OD reading from week 7 to 9 was expected based upon the immunization 
schedule, Table V.  The OD increased after week 9 because of the scheduled 
immunization.  Codon optimized immunized rabbits showed a slight decrease in binding 
antibody from week 11 to 13, while in the wild type immunized rabbits, a much sharper 
decrease was noted over the same time period (Figure 10).  This is because the codon 
optimized sequence elicits a higher immune response, creating more specific antibodies 
which will last longer in the animal’s immune system. 
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Figure 10:  Temporal ELISA of rabbit immune response to H1 DNA vaccine.  
H1.HA0.dTM antigen were produced from DNA in 293 T cells. Rabbits # 316 and 317 
were immunized with the optimized vaccine and rabbits # 381 and 382 were immunized 
with the wild type vaccine.  Optimal results were seen in rabbits immunized with the H1 
codon optimized vaccine.  Arrows indicate week at which an immunization was given. 
 
 A titration was performed to observe titer points as seen in Figure 11.  Rabbits 
immunized with the codon optimized sequence showed both higher initial OD readings 
(Figure 11), and higher titer points (Figure 12).  The codon optimized animals reached a 
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9 fold higher titer point showing a much higher immunogenicity.  Codon optimized 
animals reached a higher peak than wild type animals, and reached their peak at a quicker 
pace.  This shows that not only can a higher antibody response be elicited using codon 
optimized DNA vaccines, but also that it is reached at a faster rate allowing for the 
potential of increased neutralization of the influenza virus.   
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Figure 11:  ELISA titration of rabbit sera.  Sera sample were analyzed from bleed V 
with a starting dilution of 1:5000, then a 3x series dilution was performed.  Rabbits R # 
316 and 317 were immunized with codon optimized construct, while R # 381 and 382 
were immunized with the wild type sequence.  R # 317 Bleed I was used as a pre-
immunization control and background measure. 
 36
405000 405000
3645000 3645000
0
500000
1000000
1500000
2000000
2500000
3000000
3500000
4000000
R # 381 R # 382 R # 316 R # 317
Animals
A
nt
ib
od
y 
D
ilu
tio
n
IgG titers
 
Figure 12:  IgG titers of rabbit sera.  Data based upon Figure 11.  Codon optimized 
rabbits R # 316 and 317 had titer points 9 fold higher than wild type rabbits, R # 381 and 
382. 
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DISCUSSION 
  
 The primary goal when creating a vaccine of any kind is to elicit the most antigen 
specific immune response.  For DNA vaccines, this means optimizing the gene sequence 
to have the greatest translational efficiency inside the vaccinated animal or person.  There 
are four primary steps for protein secretion: mRNA transcription from DNA, translation 
from mRNA to the amino acid sequence, protein modification on the endoplasmic 
reticulum, and lastly packing in the Golgi complex for exportation from the cell.  Codon 
optimization, to a more G + C rich content, increases the mRNA to protein transition in 
mammalian cells increasing the exportation from the cell into its surroundings (Figure 5).  
In these in vitro experiments involving transfected 293T cells, the immunoblot membrane 
had to be exposed for a longer period of time in order to effectively visualize the weaker 
wild type expression levels.   
 Recently, codon optimization has become the method of choice for creating DNA 
vaccines, although it is a costly approach.  There are still questions about codon 
optimized DNA vaccines which remain unanswered.  First, it is not yet known to what 
extent codon optimization can improve already highly immunogenic DNA vaccines and 
some of these studies were performed with suboptimal vector components.  Second, it 
isn’t even known yet if codon optimized gene inserts require optimized vector 
components to reach optimal immunogenicity.  Also, the mechanism to which codon 
optimization affects DNA vaccine immunogenicity is not well characterized and will 
need to be to create the safest and most effective influenza DNA vaccines.  The addition 
of a tPA leader sequence would increase secretion levels of the protein, which when 
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coupled with codon optimization can increase the immunogencity of DNA vaccines 
(Wang, 2005A).    
 Two primary conclusions can be reached from this study.   The first is that codon 
optimization both increases expression (Figure 5) and elicits a higher immune response in 
animal models Figures 8 and 12).  The second is that gene gun immunization produces a 
greater immune response in animals as compared to intramuscular injection (Figure 6).  
This data supports reports by Andre et al. (1998) and shows that the result is the same for 
different proteins ranging from gp120 in HIV to HA in influenza.  Andre et al. found a 
10-50 fold higher expression level in 293T cells via western blot and in our studies, a 
relatively similar result was found (Figure 5).   
 In the influenza virus system, it has been reported that DNA vaccines stimulate a 
broader immunity than subunit or inactivated-virus vaccines (Donnelly et al., 1995; 
Montgomery et al., 1993).  The introduction of cross-reactive immunity might be further 
augmented with a multigene DNA immunization strategy, which has been previously 
shown with malaria (Doolan et al., 1996) and mycoplasma (Barry et al., 1995).  Future 
studies in the influenza project in the Nucleic Acid Vaccine Lab include multigene 
vaccines including H1, H3 and H5.  An ongoing animal study is currently researching 
optimized H1 + H3 DNA vaccines.  Various immunization schedules and procedures are 
being implemented, including the ‘prime-boost’ methodology, to find ways to create the 
greatest immune response.   
 The results of this Major Qualifying Project demonstrate the ability of modern 
science to create a vaccine which significantly increases the protective ability of “old 
science” vaccines.  It is my hope that DNA vaccines will one day dominate the vaccine 
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industry because of both their efficacy and safety.  Although DNA vaccine related 
immune responses may be most greatly increased with the prime-boost method 
(Richmond et al., 1998), not all people can boosted with current flu vaccines, which 
would be used as boosts, because of egg allergies.  In order to bypass this problem, future 
research must be completed as to prevent both seasonal flu illness as well as global 
pandemics. 
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